SCHEMBL6078644

SCHEMBL6078644

O=CNCCCc1ccc(F)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ CHRM2 P08172 1/20 0.48
▸ TAAR1 Q96RJ0 2/20 0.47
▸ SCN5A Q14524 1/20 0.46
▸ KCNH2 Q12809 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL350049 0.88 TAAR1 (0.55) CHRM2TAAR1L3MBTL1KDM4EALDH1A1
SCHEMBL6849670 0.81 LMNA (0.57) NPC1RAB9ACHRM2TAAR1L3MBTL1
SCHEMBL29822682 0.81 ESRRG (0.49) CHRM2KDM4EALDH1A1SIGMAR1SLC6A3
SCHEMBL5538860 0.80 HDAC1 (0.50) TAAR1
SCHEMBL1356645 0.80 SIGMAR1 (0.65) L3MBTL1KMT2ASIGMAR1
SCHEMBL3242822 0.78 TAAR1 (0.46) CHRM2TAAR1
SCHEMBL5514998 0.77 HRH1 (0.46) NPC1RAB9AALDH1A1KMT2ASIGMAR1
SCHEMBL8129476 0.77 SIGMAR1 (0.41) ALDH1A1KMT2ASIGMAR1
SCHEMBL8763412 0.77 LMNA (0.50) TAAR1CA12CA1CA2CA4
SCHEMBL12500340 0.77 TSHR (0.46) KCNH2KMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 — — US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 — — US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF NPC1 130/4885RAB9A 2755/4885CHRM2 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback